AAD 2025: Atopic Dermatitis Preview

Pooled Safety and Local Tolerability of Roflumilast Cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Trials of Patients With Atopic Dermatitis: Subgroup Analysis of Patients With Prior Inadequate Response, Intolerance, and/or Contraindications to Topical Treatments

Simpson, E et al.

Poster Number 62155

Roflumilast Foam 0.3% in Patients With Scalp and Body Psoriasis: Improvements in Patient-Reported Outcomes (ARRECTOR)

Gooderham, M et al.

Poster Number 62151

Long-Term Safety of Ruxolitinib Cream in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Adverse Events of Interest from the TRuE-AD1 and TRuE-AD2 Phase 3 Studies ​

Abstract: #64524

Association of Ruxolitinib Cream Initiation with Reduction in Use of Other Topical Treatments, Oral Corticosteroids, and Biologics for Atopic Dermatitis, Regardless of Previous Use of Biologics​ ​

Abstract: #64526

52-Week Disease Control and Safety with As-Needed Application of Ruxolitinib Cream in Children Aged 2 to 11 Years with Moderate and/or More Extensive Atopic Dermatitis: Subgroup Analysis from the TRuE-AD3 Study ​

Abstract: #64656

Lebrikizumab Improves Itch, Itch Interference on Sleep and Skin Pain in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab

Presented by Dr. Gil Yosipovitch

Dupilumab Treatment Significantly Reduces Age-Dependent Total IgE Levels in Young Children With Atopic Dermatitis (Poster #64623)

Dupilumab Treatment Improves Skin Barrier Function in Adolescent and Adult Patients With Atopic Dermatitis: Results from the BALISTAD and BALISTAD-CN Studies (Poster #63413)

Dupilumab Normalizes Filaggrin Processing and Improves Clinical Outcomes in Children With Moderate-to-Severe Atopic Dermatitis (Poster #61982)

Growth Analysis in Children Aged 6 to 11 Years with Severe Atopic Dermatitis and Impact of up to 52 Weeks of Dupilumab Treatment on Height

(Oral Presentation #62057, March 7, 4:40 p.m.)

Dupilumab Safety and Efficacy Up To 3 Years in Children Aged 6 Months to 11 Years With Atopic Dermatitis (Poster #62960)

Baseline Growth Analysis of Children and Adolescents With Moderate-to-Severe Atopic Dermatitis Enrolled in Phase 3 Dupilumab Trials

(Oral Presentation #62286, March 7, 10:00a.m.)

Dupilumab Improves Patient-Reported Outcomes in Patients of Color Aged Less
Than 12 Years With Atopic Dermatitis: 4-Year Results from the PEDISTAD Registry

(Poster #64507)

Real-World Effectiveness of Dupilumab in African American Patients With Atopic Dermatitis: 3-Year Data from the PROSE Registry (Poster # 64411)

Dupilumab Treatment Corrects Upregulation of Type 2 Cytokines Cascades and Improves Pruritus Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis(Poster # 63364)

Sustained Disease Control Among Adults With Moderate-to-Severe Atopic Dermatitis in Clinical Practice: 5-Year Follow-up Results From the RELIEVE-AD Study (Oral Presentation #63519, March 8, 10 a.m.)

Real-World Treatment Outcomes of Systemic Treatments for Moderate-to-Severe Atopic Dermatitis in Children Aged Less Than 12 Years from Racial Minority Groups: 4-Year Results from the PEDISTAD Registry (Poster #64468)

Design and Rationale of ARMADA-AD Disease Registry: An International, Prospective, Observational Registry to Characterize Unmet Needs and Evaluate Real-World Effectiveness and Safety of Systemic Therapies in Adults and Adolescents With Atopic Dermatitis

Poster #60502

Amlitelimab Reduces Th2-, Th1-, and Th17/22-Related Cytokines and Chemokines in Adults With Moderate-to-Severe Atopic Dermatitis): Results From an Exploratory Analysis of the Phase 2b STREAM-AD Study (Poster #62188)

Impact of amlitelimab (an anti-OX40 Ligand antibody) on Maintenance of Itch Response in Atopic Dermatitis: Results from the 52-Week STREAM-AD Phase 2b Study (Poster #62198)

Interim Results of RIVER-AD: 28-Week Open-Label Safety and Efficacy of amlitelimab in Patients With Atopic Dermatitis Not Initially Achieving Clinical Response at Week 24 of the STREAM-AD Phase 2b Tria (Poster # 63598)